[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100464610":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Sumitomo Pharma Switzerland GmbH","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Main cohort",null,"All eligible patients",[13],"Biological: Cultured Thymus Tissue",{"label":15,"type":10,"description":16,"interventionNames":17},"Secondary cohort","All eligible patients who survived 1 year post treatment",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Cultured Thymus Tissue","Product will be surgically administered into the quadriceps",[9,15],[25,26],"RETHYMIC","allogeneic cultured thymus tissue-agdc",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"John Sleasman, M.D.","CONTACT","919-684-9914","john.sleasman@duke.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Duke University School of Medicine","RECRUITING","Durham","North Carolina","27710","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-78.89862,35.99403,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100464610","congenital-athymia-patient-registry-100464610",false,"NCT05329935","Congenital Athymia Patient Registry","Congenital Athymia Patient Registry of RETHYMIC","Inclusion Criteria:\n\n* Pediatric patients diagnosed with Congenital Athymia:\n\n  * Who are scheduled for implantation with RETHYMIC within the next 30 days, or who were treated with RETHYMIC within the previous 60 days.\n  * Who have provided written informed consent directly, or written informed consent has been provided by the patient, the parent, or legal guardian.\n\nExclusion Criteria:\n\n* Written informed consent cannot be obtained.","ALL","0 Years","21 Years",{"count":63,"type":64},75,"ESTIMATED","OBSERVATIONAL","This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.\n\nClinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).",[68,69,70],"Complete DiGeorge Anomaly","Complete DiGeorge Syndrome","Congenital Athymia",[70],"2025-08-14",{"date":74,"type":75},"2025-08-19","ACTUAL",{"date":77,"type":75},"2022-05-25",{"date":79,"type":64},"2026-04",{"name":5,"class":6},1]